Enanta Pharmaceuticals公布Zelicapavir治疗高风险成人呼吸道合胞病毒(RSV)2B期研究的积极顶线结果

美股速递
Sep 29, 2025

Enanta Pharmaceuticals发布了其药物Zelicapavir用于治疗高风险成人呼吸道合胞病毒(RSV)的2B期临床试验积极顶线结果。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10